Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology | Psychiatry/Psychology
Disease Category: Attention Deficit/Hyperactivity Disorder (ADHD - Adults)
Trial Information
Efficacy of Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents and Young Adults with Substance Use Disorders (SUD)
The Pediatric Psychopharmacology Department at the Massachusetts General Hospital is looking for adolescents and young adults, ages 15-30, with symptoms of Attention-Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD) to participate in a research study designed to examine the safety and efficacy of an investigational drug when used to treat adolescents and young adults with ADHD and SUD. Participation in this study involves up to 20 clinic visits over 20 weeks. Subjects will receive cognitive behavioral therapy for 2 to 6 weeks for their substance use, and will then have a 50% chance of taking the study drug or a placebo (sugar pill). Participants will receive study-related medical care and medication at no cost, as well as up to $200 compensation for their time. If interested, please contact the MGH Pediatric Psychopharmacology Department at (617) 724-ADHD.
Kerry Brodziak
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114
Phone: 617-724-ADHD
EMail: kbrodziak@partners.org
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
